CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...

Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation ...

These two dividend stocks are focused on steady, repeatable payouts with yields up to 12.5%. Here's what income investors ...

Entrepreneurs, business owners, and well-known names in the Wiregrass gathered in downtown Dothan today for the second ...

Keynote speaker will be the Rev. Barbara Haigler, pastor of Clinton Chapel A.M.E. Zion Church, presiding elder of the ...

Research on system architecture has proved a very fundamental tradeoff that applies to ubiquitous connectivity. It tells us ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

GWM has announced discounts across the brand’s entire range, and adds further ABN discounts on some models for eligible ...

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...

Meanwhile, Prospera has added its first team in Vermont, while Concurrent gets bigger in Texas with a $385 double acquisition ...

Reaching Alpha Centauri within a single human lifetime has long sounded like science fiction, yet a new generation of nuclear ...